Evolution of the Average Target: Bausch Health Companies Inc.

Evolution of the Target Price: Bausch Health Companies Inc.

Changes in Analyst Recommendations: Bausch Health Companies Inc.

16c1d7577b6a4a70a148fc299646b10.Psll1fKGNQKdCTQB-xK9nvhJKGHJm_7AhBRIhPUezpU.X5s1vpnwUlrIZUNMsSLlr4ktQguj0Mar00MZtoIpqNcMvBTsovBZeOhReQ~f5fa958491baa745b74e7ebfe066fb10
04-30 RBC Keeps Sector Perform Rating, US$9.00 Price Target, on Bausch Health After Strong Q1 MT
04-27 RBC Capital Trims Bausch Health Companies Price Target to US$9.00; Maintains Sector Perform MT
04-27 Bausch Health's Q1 Total Prescriptions Hurt by Exit From Federal Drug Pricing Programs, RBC Says MT
04-27 RBC Cuts Price Target on Bausch Health to $9 From $10, Keeps Sector Perform Rating MT
01-27 RBC Previews Bausch Health's Fourth-Quarter Results MT
01-07 Truist Securities Adjusts Price Target on Bausch Health to $8 From $7, Maintains Hold Rating MT
25-10-29 Needham Keeps Hold on Bausch + Lomb After Q3, Says Would Like Clarity on Bausch Health Separation MT
25-10-22 RBC Maintains Market Perform Rating, US$10 Price Target on Bausch Health Companies MT
25-07-31 RBC Maintains US$10 Price Target, Sector Perform Rating on Bausch Health MT
25-04-21 BofA Cuts Price Target on Bausch Health to $5 From $7 MT
25-04-07 Correction: Bausch Health's Q1 Revenue Expected to Narrowly Miss Consensus Estimates, RBC Capital Says MT
25-04-07 Bausch Health's Q1 Revenue Expected to Narrowly Miss Consensus Estimates, RBC Capital Says MT
25-04-07 RBC Previews Bausch Health's Q1 MT
25-04-07 RBC Capital Adjusts PT on Bausch Health Companies to $8.50 From $9, Keeps Sector Perform Rating MT
25-02-03 BofA Adjusts Price Target on Bausch Health Companies to $7 From $6 MT
25-01-30 Bausch Health Q4 Results to Focus on 2025 Outlook, Potential Full Separation of Bausch + Lomb, RBC Says MT
25-01-30 RBC Lowers Price Target on Bausch Health to $10 From $11, Keeps Sector Perform Rating MT
24-11-01 RBC on Bausch Health's Q3 MT
24-11-01 RBC Lifts Price Target on Bausch Health to $11 From $10, Keeps Sector Perform Rating MT
24-10-22 RBC Previews Bausch + Lomb's Q3 MT
24-08-02 RBC Cuts Bausch Health Price Target to US$8.50, Maintains Sector Perform MT
24-08-02 RBC Cuts Price Target on Bausch Health to $8.50 From $10, Keeps Sector Perform Rating MT
24-08-02 Top Premarket Decliners MT
24-08-02 Piper Sandler Downgrades Bausch Health to Underweight From Neutral, Adjusts Price Target to $3 From $9 MT
24-07-25 Truist Adjusts Bausch Health Companies' PT to $7 From $8, Maintains Hold Rating MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+4.61%
+0.79%
+5.48%
+6.72%
-0.25%
+25.02%
-1.66%
-2.13%
+21.93%
Average +6.72%
Weighted average by Cap. +5.42%
See all sector consensus

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
7
Last Close Price
4.780USD
Average target price
7.400USD
Spread / Average Target
+54.81%
High Price Target
9.000USD
Spread / Highest target
+88.28%
Low Price Target
6.000USD
Spread / Lowest Target
+25.52%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

RBC Capital Markets
Truist Securities
BofA Securities
Jefferies & Co.
TD Cowen
Piper Sandler
BMO Capital
Stifel Nicolaus
JPMorgan Chase
Barclays
Spin-Off Research
HC Wainwright
J.P. Morgan Chase
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
7
Last Close Price
4.780USD
Average target price
7.400USD
Spread / Average Target
+54.81%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. BHC Stock
  4. BHC Stock
  5. Consensus Bausch Health Companies Inc.